{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:11:57Z","timestamp":1789110717098,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2035274"],"award-info":[{"award-number":["2035274"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Medical Journal of Australia"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The growing popularity of glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101 RAs) has driven off\u2010label prescriptions and supply shortages, raising equity concerns for First Nations peoples disproportionately affected by diabetes. Pharmaceutical companies have simultaneously accelerated their marketing through disease\u2010awareness campaigns, sponsored events and telehealth models, with many campaigns prominently featuring women of colour, including First Nations women. In this perspective article, we argue, from a commercial determinants of health perspective, that pharmaceutical companies often influence perceptions of body image, medicines policy and prescribing without addressing the systemic conditions driving First Nations health inequity. We urge clinicians and policymakers to ensure decisions remain free from commercial influence.<\/jats:p>","DOI":"10.5694\/mja2.70246","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:25:49Z","timestamp":1783686349000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Weight Loss Medication Marketing and First Nations People: Disease Awareness or Corporate Profit?"],"prefix":"10.5694","volume":"224","author":[{"given":"Troy","family":"Walker","sequence":"first","affiliation":[{"name":"Institute for Health Transformation, Global Centre for Preventive Health and Nutrition, School of Health and Social Development, Faculty of Health Deakin University  Geelong Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Sherriff","sequence":"additional","affiliation":[{"name":"Poche Centre for Indigenous Health, Faculty of Medicine and Health, University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Browne","sequence":"additional","affiliation":[{"name":"Institute for Health Transformation, Global Centre for Preventive Health and Nutrition, School of Health and Social Development, Faculty of Health Deakin University  Geelong Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102025\u2010101735"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)00013\u20102"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102021\u2010052636"},{"key":"e_1_2_11_5_1","volume-title":"Weight Loss Drug Wegovy to Be Subsidised for Australians With Severe Obesity","author":"Manfield E.","year":"2026"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1145\/3555102"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/00913367.2025.2593673"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0815-8"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"e_1_2_11_10_1","volume-title":"Exenatide, Injection, 5 Microgram Per Dose, 10 Microgram Per Dose, Pre\u2010Filled Pen, 60 Doses, Byetta","author":"Australian Government, Department of Health, Disability and Ageing","year":"2007"},{"key":"e_1_2_11_11_1","doi-asserted-by":"crossref","unstructured":"M. O.Falster J.deOliveira Costa T.Milder et\u00a0al. \u201cThe GLP\u20101 RA Boom: Trends in Publicly Subsidised and Private Access in Australia 2020\u20102025 \u201dmedRxiv 2025.10.30.25339120 2025 https:\/\/doi.org\/10.1101\/2025.10.30.25339120.","DOI":"10.1101\/2025.10.30.25339120"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102021\u2010059716"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2025.06.1019"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2023.022"},{"key":"e_1_2_11_15_1","unstructured":"Diabetes Australia \u201cCalls to Prioritise Diabetes Medicines for Aboriginal Communities \u201daccessed 22 March 2024 https:\/\/www.diabetesaustralia.com.au\/mediarelease\/prioritise\u2010diabetes\u2010medicines\u2010aboriginal\u2010communities\/."},{"key":"e_1_2_11_16_1","unstructured":"\u201cPharmaceutical Benefits Advisory Committee (PBAC) Meeting Outcomes November 2025 PBAC Meeting 2025 \u201daccessed June 2026 pbac\u2010web\u2010outcomes\u201011\u20102025\u2010v2.pdf."},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.70160"},{"key":"e_1_2_11_18_1","volume-title":"National Guide to Preventive Healthcare for Aboriginal and Torres Strait Islander People","author":"Kelly R.","year":"2024"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194740"},{"key":"e_1_2_11_20_1","unstructured":"J. P.Morgan \u201cHow Demand for (and Supply of) Weight Loss Drugs is Playing Out in 2026 \u201daccessed Mar 2026 https:\/\/www.jpmorgan.com\/insights\/global\u2010research\/current\u2010events\/obesity\u2010drugs."},{"key":"e_1_2_11_21_1","unstructured":"Reuters \u201cNovo Nordisk Regains Crown as Europe's Most Valuable Company \u201dReuters 13 June 2025 accessed Mar 2026 https:\/\/www.reuters.com\/business\/healthcare\u2010pharmaceuticals\/novo\u2010nordisk\u2010regains\u2010crown\u2010europes\u2010most\u2010valuable\u2010company\u20102025\u201006\u201013\/?utm_source=chatgpt.com."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19320"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/07359680903304328"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2025.118132"},{"key":"e_1_2_11_25_1","unstructured":"Australian Government Department of Health Disability and Ageing \u201cTherapeutic Goods Act 1989 \u201daccessed Mar 2026 https:\/\/www.tga.gov.au\/resources\/legislation\/therapeutic\u2010goods\u2010act\u20101989."},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/medethics\u20102017\u2010104504"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1559"},{"key":"e_1_2_11_28_1","unstructured":"Novo Nordisk Novo Nordisk Forms Aboriginal and Torres Strait Islander Health Advisory Council to Advance Health Equity for Aboriginal and Torres Strait Islander Peoples[Media Release] 2025 accessed June 2026 https:\/\/www.novonordisk.com.au\/content\/dam\/nncorp\/au\/en\/images\/news\u2010and\u2010publication\/pdf\/Media\u2010release_Novo\u2010Nordisk\u2010Forms\u2010Aboriginal\u2010and\u2010Torres\u2010Strait\u2010Islander\u2010Health\u2010Advisory\u2010Council.pdf."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/11771801241253291"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40337\u2010025\u201001243\u20109"}],"container-title":["Medical Journal of Australia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.5694\/mja2.70246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.5694\/mja2.70246","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.5694\/mja2.70246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:06:52Z","timestamp":1785377212000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.5694\/mja2.70246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.5694\/mja2.70246"],"URL":"https:\/\/doi.org\/10.5694\/mja2.70246","archive":["Portico"],"relation":{},"ISSN":["0025-729X","1326-5377"],"issn-type":[{"value":"0025-729X","type":"print"},{"value":"1326-5377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70246"}}